Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?

But Phase III Is Already Enrolled

Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.

Liver cancer, CT scan upper abdomen.
US CRL For New Combo May Shape Evolving HCC Market • Source: Shutterstock

While the US Food and Drug Administration’s decision to issue a Complete Response Letter (CRL) on Merck & Co. and Eisai Co., Ltd.’s bid for accelerated approval of their Keytruda (pembrolizumab) and Lenvima (lenvatinib) combination in first-line unresectable hepatocellular carcinoma (HCC) may be a setback, the companies are already well ahead with another supporting trial in this setting.

But in the meantime, another new combo from Roche has already gained approval in the indication on the back of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Shigella Vaccine Pipeline And Why It Matters

 
• By 

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.